BTK inhibitor PCI-32765
Phase 1Small molecule
BTK inhibitor PCI-32765 is one of 3 small molecule programs targeting Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Active, not recruiting
Competition
Competitive Landscape
2 competitors in Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 1
Bendamustine Hydrochloride
SSymBio Pharmaceuticals
Phase 1
BTK inhibitor PCI-32765
KKami Maddocks, MD
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BTK inhibitor PCI-32765. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- KKami Maddocks, MD